Basic information
Biomarker: VEGF
Histology type: endometrioid endometrial carcinoma
Cohort characteristics
Country: Finland
Region: Tampere
Followed up time :
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
98 | EC | 98 |
Sample information
Conclusion: The results of the present study suggest that preoperative serum VEGF concentration correlates with the presence of metastases in endometrioid endometrial carcinoma.
Sample type : serum
Sample method: ELISA/immunohistochemistry
Expression pattern : concentration(metastases VS without metastases,743 pg/mL [546-1,183 pg/mL] vs. 383 pg/mL [31-1,524 pg/mL] )
Disease information
Statictics: Mean (SD);Range
Cohort age: 66.9±9.0;33–87
Related information
Funtion Uniprot: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).
UniProt ID: P15692
UniProt Link: https://www.uniprot.org/uniprotkb/P15692/entry
Biological function from UniProt: #Angiogenesis #Differentiation
Molecular function from UniProt:
Tissue specificity from UniProt: Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.
Subcellular UniProt: #Secreted
Alternative name from UniProt:
Recommended name: Vascular endothelial growth factor A
Gene name from HGNC: Vascular endothelial growth factor A
HPA class: Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Human disease related genes Plasma proteins RAS pathway related proteins
AlphaFold DB: P15692
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P15692
Induction: By hypoxia. Regulated by growth factors, cytokines, gonadotropins, nitric oxide, hypoglycemia and oncogenic mutations.
HPA link: https://www.proteinatlas.org/ENSG00000112715-VEGFA
Tissue specificity RNA from HPA: Low tissue specificity
Tissue expression from HPA: Ubiquitous cytoplasmic expression.
Single cell type specificity Cell type enhanced (Alveolar cells type 1, Muller glia cells)
Immune cell specificity: Not detected in immune cells
Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable), liver cancer (unfavorable), endometrial cancer (unfavorable), urothelial cancer (favorable) and cervical cancer (unfavorable)
Pathology link: https://www.proteinatlas.org/ENSG00000112715-VEGFA/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000112715-VEGFA/pathology/endometrial+cancer
Phenotype ID: 603933
Disease: Microvascular complications of diabetes 1 (MVCD1)
Note1: Disease susceptibility is associated with variants affecting the gene represented in this entry
OMIM: 192240
OMIM link1: https://www.omim.org/entry/603933
OMIM link2: https://www.omim.org/entry/192240
HGNC ID: HGNC:12680
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12680